ArticleFrontiers in immunology2026
Explainable machine learning-based mortality risk stratification for older adults with COVID-19: pinpointing core immunological biomarkers and revealing dose-threshold effects.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Older adults are the high-risk group for COVID-19-related death. This study aimed to develop an accurate, efficient, clinically interpretable machine learning (ML) model for predicting mortality risk in this population, using only routine hematological indicators at admission to avoid extra medical costs and radiation exposure. Methods: 2393 COVID-19 patients were enrolled in this retrospective study. Missing values were imputed via Random Forest. RandomOverSampler was utilized during model training to alleviate moderate class imbalance. Feature selection was conducted following the maximum relevance-minimum redundancy principle. Five ML algorithms-Logistic Regression (LR), Support Vector Machine (SVM), Random Forest (RF), XGBoost (XGB), Light Gradient Boosting Machine (LGBM) were optimized via bayesian optimization (BO). We performed 10 rounds of random stratified data splitting; models were fitted on the training set, with intermediate screening and hyperparameter optimization implemented on the validation set. The independent held-out test set was strictly reserved for final performance evaluation. Model performances were assessed using the ROC curve, accuracy, precision, recall, F1-score and brier score. Calibration curve evaluated concordance between predicted probabilities and actual outcomes, and decision curve analysis (DCA) quantified net clinical benefit in clinical practice. Shapley additive exPlanations (SHAP) values and partial dependence plots (PDPs) interpreted feature importance and their associations with mortality risk. A simplified model was further developed using the top 10 key features identified by SHAP analysis and a corresponding risk prediction system was constructed to facilitate clinical application by physicians. Results: The LGBM model achieved the best comprehensive performance: AUC of 0.973, recall of 0.924, accuracy of 0.918, F1-score of 0.918, NPV of 0.923, and Brier score of 0.064. It outperformed other algorithms in computational efficiency and cross-dataset stability. Top 10 key features identified included basophil percentage (BA%), C-reactive protein (CRP), procalcitonin (PCT), D-dimer (D-dimer), AST/ALT ratio, cardiac troponin I (cTnI), standard bicarbonate (SB), age, aspartate transaminase (AST), and oxygen saturation (SaO Conclusion: This study developed a TPE-LGBM model based on routine hematological indicators to predict mortality risk in older adults with COVID-19. The model demonstrated favorable accuracy, efficiency, and interpretability, suggesting the potential value of applying explainable machine learning to address unmet medical needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.